BRAF and colorectal carcinoma: However, improved molecular stratification and identification of different biological subtypes now offers treatment approaches with chemotherapy-free regimens for selected patients, i.e., ICI monotherapy in MMDr/MSI-H mCRC and targeted combination therapy with cetuximab and encorafenib for BRAF-mutated CRC.